Drugs / MK-8777
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00610441 | Apr 2008 → Mar 2009 | attention deficit-hyperactivity disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 2 | NCT00610649 | Sep 2007 → Nov 2008 | depressive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00610441 ↗ |
| Known as | Org 26576 | “This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).” NCT00610441 ↗1“Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.” NCT00610649 ↗ |
| Known as | SCH 900777 | “This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).” NCT00610441 ↗1“Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.” NCT00610649 ↗ |
| Route | Oral | “Orally administered capsules containing either 50 mg or 100 mg MK-8777.” NCT00610649 ↗ |